Short-Term Active Safety Surveillance of the Spikevax and Nuvaxovid Priming Doses in Australia

Australia commenced administration of the Spikevax (Moderna mRNA-1273) COVID-19 vaccine in August 2021 and Nuvaxovid (Novavax NVX-CoV2373) in January 2022. This study describes the short-term safety profile of priming doses of the Spikevax and Nuvaxovid vaccines given between September 2021 and September 2023.

Citation:
Reynolds R, Tay E, Dymock M, Deng L, ……. Marsh JA, Snelling T, Wood N, Macartney K. Short-Term Active Safety Surveillance of the Spikevax and Nuvaxovid Priming Doses in Australia. Vaccines. 2024;12(9).

Keywords:
COVID-19; Moderna; Novavax; active surveillance; adverse events; safety; vaccine

Abstract:
Australia commenced administration of the Spikevax (Moderna mRNA-1273) COVID-19 vaccine in August 2021 and Nuvaxovid (Novavax NVX-CoV2373) in January 2022. This study describes the short-term safety profile of priming doses of the Spikevax and Nuvaxovid vaccines given between September 2021 and September 2023.